Medicare Enrolled

Dr. Jeffrey Cary, MD

Pulmonary Disease · Seattle, WA
515 MINOR AVE, Seattle, WA 98104
2063869500
Registered in NPPES since 2005
NPI: 1235129131 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Cary from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Cary? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Cary

Dr. Jeffrey Cary is a pulmonary disease specialist in Seattle, WA, with 20 years of NPI registration.

Between the years covered by Open Payments, Dr. Cary received a total of $145,478 from 8 pharmaceutical and/or device companies across 246 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Cary is High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years of NPI registration $145,478 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$145,478
Total received (2018-2024)
Avg $20,783/year across 7 years
Top 4% in WA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
8
Companies
246
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,935
2023
$15,649
2022
$16,101
2021
$3,927
2020
$17,753
2019
$46,082
2018
$42,030

Payments by company (2024)

Mylan Specialty L.P.
$3,913
Boston Scientific Corporation
$23
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Sunovion Pharmaceuticals Inc.
$63,824
Mylan Specialty L.P.
$50,310
Genentech USA, Inc.
$26,107
Genentech, Inc.
$3,665
AstraZeneca Pharmaceuticals LP
$842
Boehringer Ingelheim Pharmaceuticals, Inc.
$396
GlaxoSmithKline, LLC.
$168
Boston Scientific Corporation
$166
Top 3 companies account for 96.4% of all-time payments
Associated products mentioned in payments ›
Actemra · EkoSonic · Esbriet · GENERAL PULMONARY · LONHALA MAGNAIR · Lonhala Magnair · OFEV · SYMBICORT · TRELEGY ELLIPTA · YUPELRI · Yupelri
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a pulmonary disease specialist in Seattle?
Compare pulmonary diseases in the Seattle area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases in nearby ZIP areas
114
County median income
$122,148
Nearest hospital to ZIP centroid (approximate)
HARBORVIEW MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry ✓ NPPES NPPES snapshot; verify current record
Medicare Enrollment ✓ PECOS PECOS snapshot
Practice Data — No data N/A
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Cary is a pulmonary disease specialist, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Does Dr. Cary receive payments from pharmaceutical companies?
Yes. Dr. Cary received a total of $145,478 from 8 companies across 246 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Cary) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →

Explore related providers

Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Seattle
Browse pulmonary diseases in Seattle ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in WA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in WA
Which WA pulmonary diseases receive the most from drug and device companies.
By company
Sunovion Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Sunovion Pharmaceuticals Inc.
By company
Mylan Specialty L.P. Payments to Doctors
See all physicians who received payments from Mylan Specialty L.P.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →